28 July - Sunday

Preliminary program - subject to change.

10:00 - 13:00

Concurrent Short Courses 1 and 2

Short Course 1: Advances in the Role of Transporters in Drug Development
Chair: Yingying Guo, Eli Lilly and Company, Indianapolis, Indiana, USA

The Next Frontier in ADME Research: Predicting and Verifying Tissue Drug Concentrations Using a Proteomics and PET Imaging Approach
Jashvant Unadkat, University of Washington, Seattle, Washington, USA

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using in vitro and PBPK Modeling Approaches
Yingying Guo, Eli Lilly and Company, Indianapolis, Indiana, USA

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective from the International Transporter Consortium
Sook Wah Yee, University of California San Francisco, San Francisco, California, USA

Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
Gerry Kenna, Safer Medicines Trust, Kingsbridge, Devon, United Kingdom

Transporter DDIs – A Regulatory Perspective “Transporters in Drug Development: Scientific and Regulatory Considerations”
Lei Zhang, Silver Spring, Maryland, USA

Speaker Panel Discussion


Short Course 2: Non-P450 Enzymes in ADMET for Drug Discovery and Development
Co-Chairs: Cyrus Khojasteh, Genentech, South San Francisco, California, USA and Kouichi Yoshinari, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

An Overview of Non-P450-mediated Metabolism in Drug Development
Cyrus Khojasteh, Genentech, South San Francisco, California, USA

Role of Glucuronidation in Drug Metabolism and Toxicity
Ryoichi Fujiwara, University of Arkansas, Little Rock, Arkansas, USA

Enzymology and Clinical Importance of Reductases and Hydrolases
Matt Cerny, Pfizer Inc., Groton, Connecticut, USA

Significance of Hydrolases and Aldehyde Oxidase in Drug Toxicity
Tatsuki Fukami, Kanazawa University, Kanazawa, Japan

14:00 - 17:00

Concurrent Short Courses 3 and 4

Short Course 3: State of the Art PKPD and QSP Modeling
Chair: Piet van der Graaf, Certara, Sheffield, United Kingdom and Marjoleen Nijsen, Abbvie, Chicago, Illinois, USA

Introduction to QSP
Piet van der Graaf, Certara, Sheffield, United Kingdom

Tutorial: How to Build a QSP Model in Less than One Hour
Andrzej Kierzek, Certara, Sheffield, United Kingdom

Application of QSP in Drug Discovery
R. Adam Thompson, Abbvie, Chicago, Illinois, USA

Therapeutic Area Case Study: QSP in Immuno-oncology
Shihem Bihorel, University of Florida, Orlando, Florida, USA

Therapeutic Area Case Study: QSP in Inflammatory Disease
Kapil Gadkar, Genentech, South San Francisco, California, USA


Short Course 4: Idiosyncratic Drug-induced Liver Injury
Co-Chairs: Gerry Kenna, Safer Medicines Trust, Kingsbridge, Devon, United Kingdom and Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom

The Role of Inflammatory Mediators in Idiosyncratic Drug-induced Liver Injury
Jack Uetrecht, University of Toronto, Toronto, Ontario, Canada

Clinical Aspects of Hepatocellular and Cholestatic Drug-induced Liver Injury
Einar S. Björnsson, Landspítali - The National University Hospital of Iceland, Reykjavik, Iceland

Cellular and Animal Models of Idiosyncratic Drug-induced Liver Injury
Tsuyoshi Yokoi, Nagoya University, Nagoya, Japan

Progress Made in Understanding Genetically-inherited Susceptibility Factors, Including HLA Genotype
Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom

17:30 - 18:30

Meeting Opening and Welcome

Keynote Lecture: Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities

Lawrence Lesko, Emeritus Professor, University of Florida, Orlando, Florida, USA

Attendee and Exhibitor Meet and Greet

18:30 - 20:30